Patent · US Active

PCSK9 peptide combination vaccine and method of use

US9220762B2 · kind B2 · utility

0Cited by

0References

21Claims

0Family size

Assignee

AFFIRIS AG · AT

Inventors

Sylvia Brunner · Wien, AT
Gergana Galabova · Wien, AT
Bettina Wanko · Wien, AT
Markus Windwarder · Gänserndorf, AT
Gabriele Winsauer · Wien, AT
Guenther Staffler · Wien, AT
Claudia Juno · Wien, AT

Key dates

Filing date	Sep 13, 2012
Grant date	Dec 29, 2015
Priority date	—
Expiry date	Sep 13, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y304/21061
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A vaccine or immunogenic composition comprising at least two fragments of proprotein convertase subtilisin/kexin type 9 (PCSK9) where one fragment contains at least 9 consecutive residues of residues 153 to 165 of PCSK9 and the other fragment contains at least 9 consecutive residues 209 to 222 of the PCSK9 (SEQ ID NO:9). Methods of treatment for hyperlipidemia, hypercholesterolemia, and atherosclerosis involving administering this vaccine.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.